Antiangiogenic and antitumor properties of cartilage

Корман Д.Б. Основы противоопухолевой химиотерапии. М. Практическая медицина. — 2006. — C.503.

Корман Д.Б. Альтернативная терапия рака // Практ. Онкол. — 2007. — № 4. С. 235-244

AE-941 // Drugs R.D. — 2004. — Vol. 5. — P. 83-89.

Barber R., Delahunt B., Grebe S.K. et al. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression ina murine model // Anticancer Res. — 2001. — Vol. 21. — P. 1065-1069.

Bargahi A., Rabbani-Chadegani A. Angiogenesis inhibitor protein fractions derived from shark cartilage // Biosci. Rep. — 2008. — Vol. 28. — P. 15-21.

Bargahi A., Hassan Z.M., Rabbani-Chadegani A. Effect of shark cartilage derived protein on the NK cells activity // Immunopharmacol. Immunotoxicol. — 2011. — Vol. 33. — P. 403-409.

Batist G., Patenande F., Champagne P. et al. Neovastat (AE-941) in refractory renal cell carcinoma patients // Ann.oncol. — 2002. — Vol. 13. — P. 1259-1263.

Beliveau R., Gingras D., Kruger E.A. et al. The antiangiogenic agent Neovastat (AE-941) inhibits vascular endothelial growth factor mediated biological effects // Clin. Cancer Res. — 2002. — Vol. 8. — P. 1242-1250.

Berbari B., Thibodeau A., Germain L. et al. Antiangiogenic effects of the oral administration of liquid cartilage extract in human // J.Surg.Res. — 1999. — Vol. 87. — P. 108-113.

Berger F., Jourdes P., Benbid A.E. AE-941 (Neovastat) showsa beneficial effect in experimental glioma and is associated with high angiostatin level in treated tumors // Proc.Am.Ass.Cancer Res. — 2001. — Vol. 42. — P. 724 (abstract 3821).

Boivin D., Gendron S. Beaulien E. et al. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis // Mol.Cancer Ther. — 2002. — Vol. — 10. — P. 795-802.

Brem H., Folkman J. Inhibition of tumor angigogenesis mediated by cartilage // J.Exp.Med. — 1975. — Vol. 141. — P. 427-439.

Bukowski R.M. AE-941,a multifunctional antiangiogenic compound: trials in renal cell carcinoma // Expert.Opin. Investig.Drugs — 2003. — Vol. 12. — P. 1403-1411.

Cassileth B., Schraub S., Robinson E. et al. Alternative medicine use word-wide: the international union against cancer servey // Cancer. — 2001. — Vol. 91. — P. 1390-1393.

Clapp C., Thebault S., Jeziorski M.C., De la Escalra C.M. Peptide hormone regulation of angiogenesis // Physiol. Rev. — 2009. — Vol. 89. — P. 1177-1215.

Davis P.F., He Y., Furneaux R.H. et al. Inhibition of angiogenesis by oral ingestion of powred shark cartilage ina rat model // Micrivascular. — 1997. — Vol. 54. — P. 178-182.

Duefias Z., Torner L., Corbacho A. et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules // Invest.Ophtalmol. Vis. Sci. — 1999. — Vol. 40. — P. 2498-2505.

Dupont E., Folardeau P. , Mousa S.A. et al. Antiangiogenic and antimetastic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue // Clin. Exp. Metastasis. — 2002. — Vol. 19. — P. 145-153.

Falardeau P., Champaguel P., Poyet P. et al. Neovastat,a naturally occuring multifunctional antiangiogenic drug, in phase III clinical trials // Semin.Oncol. — 2001. — Vol. 28. — P. 620-625.

Gabrielides C., Barreau F. A vertebrate interstitial collagenase inhibitor from bovine scapular cartilage: purification and characterization // Biochim.Biophys. Acta. — 1987. — Vol. 16. — P. 238-247.

Gingras D., Renaud N.A., Moussean M et al. Matrix proteinase inhibition by AE-941,a multifunctional antiangiogenic compound // Anticancer Res. — 2001. — Vol. 21. — P.145-155.

Gingras D., Boivin D., Deckers C. et al. Neovastat—a novel antiangiogenic drug for cancer therapy // Anticancer Res. 2003. — Vol. 14. — P. 91-96.

Gingras D., Labelle D., Nyalendo C. et al. The antiangiogenic agent Neovastat (AE-941) stimulates sue plasminogen activator activity // Invest New Drugs. — 2004. — Vol. 22. — P. 17-26.

Gonzalez R.P., Soares F.S., Fabias R.E. et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor induced angiogenesis in the rabbit cornea // Biol.Pharm.Bull. — 2001. — Vol. 24. — P. 151-154.

Gonzalez R.P., Leyva A., Morales M.O. Shark cartilage as source of antiangiogenic compounds: from basic to clinical research // Biol.Pharm.Bull. — 2001. —Vol.24. — P. 1097-1101.

Habermann T.M., Thompson C.A., Laplan B.R. et al. Complementary and alternative medicine use among long-term lymphoma survivors:a pilot study // Amer.J.Hematol. — 2009. — Vol. 84. — P. 795-798.

Hillman J.D., Peng A.T., Golliam A.C. et al. Treatment of Kaposi sarcoma with oral administration of shark cartilage ina human herpes virus 8-seropositive, human immunodeficiency virus-seronegative homosexual tis-tisman // Arch.Dermatol. — 2001. — Vol. 137. — P. 1149-1152.

Hiraki Y., Shukunami C. Angiogenesis inhibitors localized in hypovascular mesenchymal tissues: chondromodulin-1 and tenomodulin // Connect.Tissue Res. — 2005. — Vol. 46. — P. 3-11.

Horsman M.R., Alsner J., Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma // Acta oncol. — 1998. — Vol. 37. — P. 441-445.

Kang J.A., Kim J.T., Song H.S. et al. Anti-angiogenic and anti-tumor invasive activities of the tissue inhibitor metalloproteinase-3 from shark, Scyliorhinus torazawe // Biochim. Biophys. Acta—2003. — Vol. 16. — P. 59-44.

Kern B.E., Balcom L.H., Antoni B.A. et al. Troponin I peptide (Glu-94-Leu-123),a cartilage derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer // J.Gastrointest.Surg. — 2003. — Vol. 7. — P. 961-968.

Kim J., Luo W., Chen D.T. et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer // Cancer Res. — 2003. — Vol. 63. — P. 386-393.

Kinet V., Castermans K., Herkenne S. et al. The angiostatic protein 16k human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells // Endocrinology—2011. — Vol. 152. — P. 4062-4071.

Kitahara H., Hayami T., Tokuhaga K. et al. Chondromodulin-1 in rat articular cartilage // Arch. Histol. Cytol. — 2003. — Vol. 66. — P. 221-228.

Langer R., Conn H., Vacanti J. et al. Control of tumor growth in animals by infusion of an angiogenesis inhibitor // Proc.Natl.Acad.Sci. USA. — 1980. — Vol. 77. — 4331-4335.

Latrelle J., Batist G., Laberge F. et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer // Clin.Lung Cancer —2003. — Vol. 4. — P. 231-236.

Lee A., Langer R. Shark cartilage contains inhibitors of tumor angiogenesis // Science — 1983. — Vol. 221. — P. 1185-1187.

Lee S.-H., Kunz J., Lin S.-H. et al. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway // Cancer Res. — 2007. — Vol. 67. — P. 11045-11053.

Liang J.H., Wong K.P. The characterization of angiogenesis inhibitor from shark cartilage // Adv.Exp. Med.Biol. — 2000. — Vol. 476. — P. 209-223.

Liu N., Lapcevich R.K., Undrhill C.B. et al. Metastatin:a hyaluronan-binding complex from cartilage that inhibits tumor growth // Cancer Res. — 2001. — Vol. 61. — P. 1022 -1029.

Loprinzi O.L., Levitt R., Barton D.L. et al. Evaluation of shark cartilage in patients with advanced cancer // Cancer — 2005. — Vol. 104. — P. 176-182.

Lu C., Lee J., Komaki R. et al. Chemoradiotherapy with and without AE-941 in stage III non-small cell lung cancer: randomized phase III trial // J.Natl.Cancer Inst. — 2010. — Vol. 102. — P. 859-865.

Macotella Y., Aguilar M.B., Guzman-Morales J. et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16kDa prolactin // J.Gen. Sci. — 2006. — Vol. 119. — P. 1790-1800.

McGuire T.R., Kazakoff P.W., Hoie E.B., Friehold M.A. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium // Pharmacotherapy — 1996. — Vol. 16. — P. 237-244.

Miller D.P., Anderson G.T., Stark J.S. et al. Phase I/II trial of the safery and efficacy of shark cartilage in the treatment of advanced cancer // J.Clin. Oncol. — 1998. — Vol. 16. — P. 3649-3655.

Milner M. Follow-up of cancer patients using shark cartilage // Alternat.Complement.Ther. — 1996. — Vol. 2. — P. 99-109.

Moses M.A., Sudnalter J., Langer R Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes // J.Cell Biol. — 1992. — Vol. 119. — P. 475-482.

Moses M.A., Wiederschain D., Wu J. et al. Troponin I is present in human cartilage and inhibits angiogenesis // Proc.Natl.Acad.Sci.USA — 1999. — Vol. 96. — P. 2645-2650.

Murray J.B., Allison K., Sudhalter J., Langer R. Purification and partial amino acid sequence of bovine cartilage-derived collagenase inhibitor // J.Biol. Chem. — 1986. — Vol. 261. — P. 4154-4159.

Oikawa T., Ashino-Fuse H., Shimamura M. A novel angiogenic inhibitor derived from Japanese shark cartilage (1). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis // Cancer Lett. — 1990. — Vol. 51. — P. 181-186.

Ostlander G.K., Cheng K.C., Wolf J.C., Wolfe M.J. Shark cartilage, cancer and growing threat of pseudoscience // Cancer Res. — 2004. — Vol. 64. — P. 84-85-8491.

Peper M.S., Montessan R., Vassalli J.D., Orci L. Chondrocytes inhibit endothelial srout formation in vitro: evidence for involvement ofa transforming growth factor-beta // J.Cell Physiol. — 1991. — Vol. 146. — P. 170-179.

Prudden J.F. The treatment of human cancer with agents prepared from bovine cartilage // J.Biological Response Mod. — 1985. — Vol. 4. — P. 551-584.

Puccio C., Mittelman A., Chun P. et al. Treatment of metastatic renal cell carcinoma with Сatrix // Proc. ASCO. — 1994. — Vol. 13. — A769.

Rabbani-Chadegani A., Abdossmadi S., Bargahi A., Yosef-Masboogh M. Identification of low-molecular weight protein (SCP1) from shark cartilage with anti-angiogenesis activity and sequence similarity to parvalbumin // J.Pharm.Biomed.Annal. — 2008. — Vol. 46. — P. 563-567.

Romano C.F., Lipton A., Harvey U.A. et al. A phase II study of Catrix-S in solid tumors // J.Biological Response Mod. — 1985. — Vol. 4. — P. 585-589.

Shen X.R., Ji D.M., Ita E.X. et al. Purification and functional characterization ofa sharkcartilage factor inhibitory to angiogenesis // Sheng Wu Hua Xue Yu Sheng (Shanghai) — 2000. — Vol. 32. — P. 43-48.

Shen X.R., Ji D.M., Ita E.X. et al. SCAIF80,a novel inhibitor of angiogenesis and its effect on tumor growth // Sheng Wu Hua Xue Yu Sheng (Shanghai) — 2001. — Vol. 33. — P. 99-104.

Sheu J.R., Fu C.C., Tsai M.L., Chung W.J. Effect of U-995,a potent shark cartilage-derived angiogenesis inhibitor on anti-angiogenesis and anti-tumor activities // Anticancer Res. — 1998. — Vol. 18. — P. 4435-4441.

Simard B., Bonamrani A., Jourdes P. et al. Induction of the fibrinolytic system by cartilage extract mediated its antiangiogenic effect in mouse genome // Microvasc. Res. — 2011. — Vol. 82. — P. 6-17.

Tabruyn S.P., Nquyen N., Cornet A.M. The antiangiogenic factor, 16-kDa human prolactin, unduses endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases // Molecular Endocrinol. — 2005. —Vol.19. — P. 1932-1942.

Takigawa M., Shirai E., Enomoto M. et al. A factor in conditional medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced be B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF) // Biochem. Int. — 1987. — Vol. 14. — P. 57-63.

Weber M.H., Lee J., Orr F.W. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model // Int.J.Oncol—2002. — Vol. 20. — P. 299-303.

White J. The challenge of rational development of complex natural products as cancer therapeutics // J.Natl. Cancer Inst. — 2010. — Vol. 102. — P. 834-835.

Zafarullah M., Su S., Marte-Pelletier J. et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal and osteartritic articular chondrocytes // J.Cekk Biochem. — 1996. — Vol. 60. — P. 211-217.

Zheng L., Ling P., Wang Z. et al. A novel polypeptide from shark cartilage with potent anti-angiogenic activity // Cancer Biol.Ther. — 2007. — Vol. 6. — P. 775-780.